Citations

Clear

4510 citation(s) found for "Scott, C".

Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia
Banerjee, Ritu, Komarow, Lauren , Li, Yixuan, Mau, Donald, Geres, Holly, Greenwood-Quaintance, Kerryl, Adler, Amos , Baliga, S, Chrysos, George , Zarkotou, Olympia , Paul, Mical, Regueiro, Dolores Sousa, Chambers, Henry, Fowler, Vance G., Patel, Robin, Group, Antibacterial Resistance Leadership, Chambers, Henry F. , Cross, Heather, Harris, Anthony D. , Duin, David van, Boucher, Helen W., Huntley, Clayton C., Raterman, Erica L., Samuel, Tamika, Moon, Kyung, Holland, Thomas L., Lodise, Thomas, Shelburne, Samuel A. , Cosgrove, Sara E., Lautenbach, Ebbing , Mehigan, Maureen, Doernberg, Sarah B. , Perdue, Sam, Singh, Tara A. , Wickward, Cathy, Souto, David A., Waller, Jason, Evans, Scott R , Banerjee, Ritu , Dodd, Andrew, Geres, Holly, Greenwood‐Quaintance, Kerryl E. , Baliga, Shrikala , Chowers, Michal , Paul, Mical, Pournaras, Spyros , Fowler, Vance G. , Patel, Robin , Evans, Scott , Hamasaki, Toshimitsu , Pettigrew, Melinda M. , Hanson, Kimberly E. , Doi, Yohei , Holland, Thomas L. , Cosgrove, Sara E. , Paterson, David L.

Mayo Clinic

JAMA | April 18, 2026 | Volume: 335 | Issue: 20 | Pages: 1762

10.1001/jama.2026.5487 | PMID 41999287 Get It

Importance Novel blood culture diagnostics provide rapid antimicrobial susceptibility testing (AST) results for bacteria causing bloodstream infections (BSIs) but have unclear clinical impact. Objective To evaluate clinical outcomes of blood culture testing using a rapid AST method compared with standard AST in patients with BSIs caused by gram-negative bacilli in regions with high prevalence of antimicrobial resistance. Design, Setting, and Participants Open-label randomized clinical trial that enrolled participants from December 2023 to May 2025 (final follow-up, June 18, 2025) at 7 medical centers in Greece (n = 2), India (n = 1), Israel (n = 3), and Spain (n = 1). Hospitalized patients (adults and children) with BSIs caused by gram-negative bacilli were eligible. Statistical analysis was conducted from August 2025 to January 2026. Intervention Patients were randomized to undergo blood culture evaluation using rapid, phenotypic AST directly from positive blood cultures plus standard susceptibility testing (n = 413) vs standard susceptibility testing alone (n = 437). Local antimicrobial stewardship teams reviewed all patients and provided treatment recommendations. Main Outcomes and Measures The primary outcome was a desirability of outcome ranking (DOOR) at day 30, with 3 categories (alive without deleterious events, alive with deleterious events, and death). The difference between rapid and standard testing was summarized as the probability that the DOOR outcomes were more desirable in the rapid testing group. Superiority was concluded if the lower limit of the 95% CI exceeded 50%. Secondary outcomes included 30-day mortality, length of hospitalization, intensive care unit admission, acquisition of hospital-acquired infections, time to effective antibiotic therapy within 3 days, and time to antibiotic escalation or deescalation within 3 days. Results Of the 899 patients randomized, 850 were included in the primary outcome analysis (median [IQR] age, 72 [21] years; 43% female). The probability that DOOR outcomes were more favorable in the rapid testing group was 48.8% (95% CI, 45.3%-52.4%). Median time to effective antibiotic therapy was not different between the groups in the as-randomized population. Median time to antibiotic escalation or deescalation was faster in the rapid testing group by 14 hours (95% CI, 6-22) in the as-randomized population. There were no differences between the groups in other secondary outcomes. In the prespecified subgroup with carbapenem-resistant infections, median time to effective therapy was 9.5 hours in the rapid testing group vs 28 hours in the standard testing group (difference, −18 hours [95% CI, −42 to 6]). Conclusions and Relevance Among patients with gram-negative bacilli BSIs, rapid blood culture AST was not superior to standard testing by DOOR. When considered with other efficacy and safety outcomes, these findings may help inform the use of rapid susceptibility testing in clinical practice. Trial Registration ClinicalTrials.gov Identifier: NCT06174649
Abstract LB364: TOP1-DNA protein complex as a predictive biomarker for NKTR-102/Rucaparib combination therapy in PARP-inhibitor resistant ovarian cancer
Venkatachalam, Annapoorna , Nitschmann, Caroline C., Flatten, Karen S., Hurley, Rachel, Hou, Xiaonan, Schenider, Paula A., Goergen, Krista M., Maurer, Matthew, Heinzen, Ethan P. , Oberg, Ann L. , Weroha, S John, Hou, Xiaonan , Correia, Cristina , Haluska, Paul , Kaufmann, Scott H. , Swisher, Elizabeth M.

Mayo Clinic

Cancer Research | April 17, 2026 | Volume: 86 | Issue: 8_Supplement | Pages: LB364-LB364

10.1158/1538-7445.am2026-lb364 Get It

Abstract Despite long-standing interest in combining topoisomerase I (TOP1) poisons with PARP inhibitors (PARPis), the mechanistic basis for the variable and often unpredictable response to this strategy remains unclear. Early preclinical studies suggested that PARP inhibition amplifies TOP1 poison-induced DNA damage, implying broad therapeutic potential; however, emerging translational and clinical data—particularly in ovarian cancer—indicate that synergy is context-dependent and governed by tumor-intrinsic features that have not been fully defined.Here we assessed determinants of response in five HR proficient ovarian cancer (OC) patient-derived xenografts (PDXs) previously treated with the SN-38 prodrug etirinotecan pegol (NKTR-102) in combination with the PARPi rucaparib (C. Nitschmann, Clin. Cancer Res. 22(2) Suppl. B50, 2016). Although all models were refractory to single-agent rucaparib, 50% exhibited enhancement of NKTR-102-induced tumor regression with the addition of rucaparib. Neither PARP1 abundance nor extent of rucaparib-mediated poly(ADP-ribose) suppression correlated with therapeutic benefit. Instead, sensitization was restricted to PDXs intrinsically responsive to NKTR-102 and was strongly associated with high levels of NKTR-102-induced TOP1-DNA covalent complexes. In further analysis, 2 of 3 resistant PDXs exhibited high levels of the ABC transporter ABCG2 despite lack of previous therapy, revealing a previously underappreciated mechanism of de novo resistance that limits effective TOP1 inhibitor activity independent of homologous recombination status. Notably, NKTR-102 response did not track with platinum/taxane sensitivity, highlighting the distinct molecular circuitry governing TOP1 poison susceptibility.Collectively, these findings demonstrate that rucaparib can potentiate NKTR-102-induced regression in tumors capable of forming abundant TOP1-DNA covalent complexes. This work identifies TOP1-DNA complex trapping and lack of ABCG2 expression as mechanistic predictors of benefit, providing an updated framework for selecting patients most likely to respond to TOP1 poison/PARPi combinations and challenging the long-standing assumption that PARP inhibition can universally resensitize tumors to TOP1 poisons. Citation Format: Annapoorna Venkatachalam, Caroline C. Nitschmann, Karen S. Flatten, Rachel Hurley, Xiaonan Hou, Cristina Correia, Paula A. Schenider, Krista Goergen, Matthew Maurer, Ethan P. Heinzen, Ann L. Oberg, S John Weroha, Paul Haluska, Scott H. Kaufmann, Elizabeth M. Swisher. TOP1-DNA protein complex as a predictive biomarker for NKTR-102/Rucaparib combination therapy in PARP-inhibitor resistant ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr LB364.
Preoperative (Neoadjuvant) Combined Chemoradiotherapy in the Management of Localized Soft Tissue Sarcoma: A Retrospective Study
Siontis, Brittany L. , Stergiopoulos, Georgios M. , Thangaiah, Judith Jebastin, Ho, Thanh P. , Grotz, Travis E. , Houdek, Matthew T. , Folpe, Andrew L. , Okuno, Scott H. , Jebastin, Judith A S , Ahmed, Safia K. , Grotz, Travis E , Houdek, Matthew T , Okuno, Scott , Siontis, Brittany L , Robinson, Steven I.

Mayo Clinic

Cancers | April 16, 2026 | Volume: 18 | Issue: 8 | Pages: 1260

10.3390/cancers18081260 | PMID 42073583 Get It

Background: Localized soft tissue sarcoma (STS) is primarily treated with surgical resection with or without radiotherapy (RT), while the role of chemotherapy (CT) as a radiosensitizer remains unclear. We report our single-institution experience with combined chemoradiotherapy (CCRT) in treating localized STS. Methods: We conducted a retrospective analysis of patients with localized STS treated at Mayo Clinic with mitomycin, cisplatin, and doxorubicin (MitoAP) concurrently with RT between 1/1/85 and 12/12/19. Results: We identified 179 patients (median age 58 years; median tumor size 9.5 cm), with 83.8% of tumors located in the extremities or trunk. Among them, 77.1% received perioperative CT in addition to CCRT, with 95% of those treated in the neoadjuvant setting. Median RT dose was 50 Gray. The 5-year disease-specific survival (DSS) was 77.9% (95% confidence interval, CI: 70.8–83.4%). The addition of perioperative CT to CCRT was associated with improved DSS compared with CCRT alone (p = 0.01, Hazard Ratio, HR: 0.48, 95% CI: 0.27–0.85). Median post-CCRT tumor viability was 30% and did not differ by CT use (p = 0.39), but varied significantly by histology (p < 0.001). Conclusions: Our institutional protocol utilizing two cycles of MitoAP with RT was well tolerated. DSS in our cohort was similar to historical data using perioperative RT alone, suggesting no clear benefit from CCRT. However, the majority of patients in our cohort were classified as high risk, which may have attenuated a potential survival benefit in the absence of appropriate comparative controls. Furthermore, additional perioperative CT to CCRT was associated with improved DSS and differential histology-specific responses in tumor viability, suggesting that a more aggressive neoadjuvant and perioperative approach may be beneficial in selected patients.
Lack of association between rifaximin and drug-resistant infections: a global multicenter inpatient cirrhosis cohort
Bajaj, Jasmohan S, Kamath, Patrick S, Wong, Florence, Xie, Qing, Topazian, Mark, Seto, Wai-Kay, Torre, Aldo, Hayes, PC, Silva, Mario, Bush, Brian J., Choudhury, Ashok, Investigators, On behalf of the EXPLANTORREDO-TAVR Registry, Fisseha, Henok , Fisseha, Henok , Bajaj, Jasmohan S. , Kamath, Patrick S. , Wong, Florence , Xie, Qing , Idılman, Ramazan , Seto, Wai‐Kay , George, Jacob , Alvares-da-Silva, Mario, BUSH, BRIAN J. , Silvey, Scott , Choudhury, Ashok

Mayo Clinic

Clinical and Molecular Hepatology | April 15, 2026 | Volume: 32 | Issue: 3 | Pages: 1321-1332

10.3350/cmh.2026.0228 | PMID 42120075 Get It

Background/Aims: Infections with drug-resistant organisms (DROs) are associated with poor outcomes in cirrhosis. Rifaximin, widely used for hepatic encephalopathy (HE), could promote cross-resistance, but data regarding clinical impact are conflicting. Aim: Determine predictors of DROs in a global cirrhosis inpatient cohort focusing on preadmission rifaximin use.Methods: From the global CLEARED consortium, we focused on cirrhosis inpatients with infections on/during admission. Clinical/demographic/medication, especially rifaximin details were recorded. The primary outcome was DRO development. Multivariable regression for DRO including clinical, medications, and country income was performed.Results: 2,949 infected inpatients (55.3 years, 62.9% male) were included. 12.2% of all and 24.4% of culture-positive infections developed DROs; these patients had higher HE (39 vs. 31%, <i>P</i>=0.003), hepatorenal syndrome (25 vs. 19%, <i>P</i>=0.006), lactulose (55 vs. 47%, <i>P</i>=0.008) and rifaximin use (34 vs. 27%, <i>P</i>=0.006) on crude comparisons but country-income distributions were similar. 29.7% were on pre-admission rifaximin, mostly HE-related; they had more advanced cirrhosis and from low/low-middle-income countries. Daptomycin was used in 1.5%, linked with DROs (5.0 vs. 1.0%, <i>P</i><0.0001) without a difference in rifaximin use (1.4 vs.1.7%, <i>P</i>=0.61). On adjusted analysis, MELD-Na (1.03, 95% CI 1.02–1.04, <i>P</i><0.001) increased, whereas male sex (0.73, 95% CI 0.58–0.92, <i>P</i>=0.008) and hepatitis-B (0.65, 95% CI 0.45–0.92, <i>P</i>=0.020) decreased DRO. Rifaximin was not associated with DROs overall (OR 1.07, 95% CI 0.80–1.43, <i>P</i>=0.65) or within income strata (high: 1.07, 95% CI 0.59–1.92, <i>P</i>=0.82, upper-middle: 1.18, 95% CI 0.74–1.85, <i>P</i>=0.49, low/low-middle: 1.04, 95% CI 0.60–1.81, <i>P</i>=0.90) despite sensitivity analyses.Conclusions: In this large global cohort of hospitalized patients with cirrhosis and infections, 12% developed infections involving DROs. 30% had pre-admission rifaximin use which was not linked with daptomycin use or with DRO development on adjusted analysis overall or across country income groups.
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
Wen, Patrick Y. , Berry, Donald A. , Buxton, Meredith , Colman, Howard , Groot, John de , Lim, Michael, Mellinghoff, Ingo K. , Perry, James, Weller, M, Blondin, Nicholas A., Butt, Omar H. , Damek, Denise M., Fuente, Macarena I. de la , Drappatz, Jan, Dunbar, Erin, Giglio, Pierre , Hyddmark, Emma Viktoria, Iwamoto, Fabio, Jaeckle, Kurt A. , Kim, Lyndon, Kling, Heather M., Lee, Eudocia Q., Mantica, Megan , Mikkelsen, Tom, Newton, Herbert B. , Walbert, Tobias , Weathers, Shiao‐Pei , Lassman, Andrew B. , Group, for the GBM AGILE Regorafenib Study, Alexander, Brian, Anker, Lars , Berry, Nicholas , Cloughesy, Tim, Connelly, Jennifer , Detry, Michelle A. , Fitzgerald, Mark, Gordon, Gary, Graves, Todd, Hu, Jethro , Hyddmark, Emma Maria Viktoria, Johnson, Adam, Kalabic, Marija, Lesser, Glenn J., Marion, Joe , Owen, Scott, Perry, James R, Peters, Katherine B., Powell, Ashley, Saunders, Christina T., Tanner, Kirk, Untch, Sarah, Wilcox, Emma, Yung, W. K. Alfred, Lim, Michael , Buxton, Meredith , de Groot, John , Mellinghoff, Ingo K , Weller, Michael , De La Fuente, Macarena , Lee, Eudocia Q , Mantica, Megan , Nabors, Louis Burt , Newton, Herbert B , Olson, Jeffrey J. , Schiff, David , Walbert, Tobias , Weathers, Shiao-Pei , Cloughesy, Timothy F , Lassman, Andrew B , Berry, Donald , Colman, Howard , Blondin, Nicolas, Drappatz, Jan , Iwamoto, Fabio M., Lee, Eudocia Q. , Mikkelsen, Tom , Nabors, Burt , Newton, Herbert B. , Cloughesy, Timothy F. , Anderson, Mark D., Cavenee, Webster K. , Connelly, Jennifer , Ellingson, Benjamin M. , Galanis, Evanthia , Gordon, Gary, Graber, Jerome J. , Khasraw, Mustafa , Lesser, Glenn J. , McGlothlin, Anna , Peters, Katherine B. , Saunders, Christina T. , Sulman, Erik P. , Tanner, Kirk, Yung, W.K. Alfred

Mayo Clinic

Journal of Clinical Oncology | April 14, 2026 | Volume: 44 | Issue: 18 | Pages: 1676-1686

10.1200/jco-25-01137 | PMID 41980234 Get It

PURPOSE GBM AGILE (ClinicalTrials.gov identifier: NCT03970447 ) is a phase II/III Bayesian adaptive platform registration trial testing multiple arms against a common control; the primary end point is overall survival (OS). Regorafenib, a multikinase inhibitor, showed OS benefit in recurrent (RD) glioblastoma in the phase II REGOMA trial and entered GBM AGILE as the first investigational arm. METHODS Patient subtypes included in the regorafenib arm of GBM AGILE were newly diagnosed unmethylated (NDU) and RD glioblastoma. Prospective defined sets of subtypes, or arm signatures, were NDU, RD, and all (NDU + RD). As the first investigational arm in GBM AGILE, regorafenib was equally randomized to the control arm. Treatment in the control arm is temozolomide + radiotherapy (in newly diagnosed) or lomustine (in RD). Efficacy was assessed by OS hazard ratio (HR), arm/control, and demonstrated when the Bayesian probability of benefit (HR <1.00) was ≥98%. Analysis was performed monthly for limited efficacy, which occurs when the Bayesian predictive power is <25% for all signatures, and determines stopping enrollment. Follow-up continued for 12 months after accrual stopped. RESULTS When the predictive power was <25% in all predefined signatures for regorafenib, accrual stopped for limited efficacy. The final analysis did not demonstrate OS improvement in the regorafenib arm in RD nor NDU glioblastoma. Median HRs were 1.05 (NDU), 1.07 (RD), and 1.07 (all) with final probabilities of benefit (HR <1.00) of 0.421 (NDU), 0.312 (RD), and 0.296 (all). Regorafenib was associated with increased toxicity relative to control. CONCLUSION GBM AGILE did not show superiority of regorafenib over control in RD (lomustine) or NDU (temozolomide + radiotherapy) glioblastoma, yet caused increased toxicities. Regorafenib has been removed from National Comprehensive Cancer Network guidelines as a treatment option for RD.
Stumped in the ICU
Copeman, Scott E., Durbin, Charles G., Eden, Douglas B., Copeman, Scott E

Mayo Clinic

Respiratory Care | April 14, 2026 | Volume: 37 | Issue: 5 | Pages: 458-461

10.1177/194336549203700511 Get It

Bronchial Mucosal Abnormalities in Idiopathic Subglottic Stenosis
Ring, Sydney , Bowen, Andrew J. , Griffin, Tessa C. , Ferguson, J. Scott , Dailey, Seth H. , Bowen, Andrew Jay , Griffin, Tessa

Mayo Clinic

The Laryngoscope | April 12, 2026 | Volume: 136 | Issue: 8 | Pages: 3527-3533

10.1002/lary.70543 | PMID 41966683 Get It

ABSTRACT Objectives Investigate synchronous lower airway findings during bronchoscopy in idiopathic subglottic stenosis (iSGS). Methods Retrospective analysis of bronchoscopic images from adult iSGS patients (January 2018–June 2021). Images were reviewed for pits, depressions, nodules, and striations distal to the cricotracheal junction. Results Forty‐eight female patients; mean age 56 years. Comorbidities: gastroesophageal reflux 34%, hypertension 34%, diabetes mellitus 25%. All patients had pits and depressions; striations in 48/48, with both longitudinal and transverse in 32/48 (66.7%), transverse only in 13/48 (27.1%), and longitudinal only in 3/48 (6.3%). Spirometry available in 32; 60% showed normal or mild–moderate fixed obstruction. Four patients had FEV 1 /FVC < 0.7; two had asthma, one COPD, and one no obstructive diagnosis; none were smokers. Conclusion Bronchial mucosal abnormalities are prevalent in iSGS and may indicate distal airway involvement. Routine flexible bronchoscopy should be considered during evaluation and surveillance. Level of Evidence 4.
Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America—A 5‐Year Analysis
Martins, Adrielly , Reddy, A. Nagarjuna, Dean, Richard, Gordon, Stuart C. , Pratt, Daniel, Li, Michael, Forman, Lisa , Lammert, Craig , Yiman, Kidist, Gallegos‐Orozco, Juan F. , Carey, Elizabeth J. , Lytvyak, Ellina , Goldberg, David S. , Naugler, Scott, Yu, Lei, Assis, David N. , Bowlus, Christopher L., Bowlus, Christopher L. , Bonder, Alan , Schlansky, Barry L , Montano-Loza, Aldo J , Lytvyak, Ellina , Goldberg, David , Assis, David N , Levy, Cynthia , Bowlus, Christopher L , Reddy, Anish , Dean, Richard , Li, Michael, Montaño‐Loza, Aldo J. , Levy, Cynthia

Mayo Clinic

Liver International | April 11, 2026 | Volume: 46 | Issue: 5 | Pages: No page available

10.1111/liv.70645 | PMID 41964270 Get It

ABSTRACT Background and Aims Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease with a high risk of malignancy and limited therapeutic options. Both the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) recommend structured baseline evaluation, fibrosis staging and longitudinal surveillance. However, real‐world adherence to these practices in North America remains unclear. Methods We conducted a retrospective cohort study of 1300 patients with PSC enrolled in the Consortium for Autoimmune Liver Diseases (CALiD) registry between 2018 and 2024 across 19 centres in North America. Guideline adherence was assessed for diagnostic measures at baseline (colonoscopy to establish IBD status and noninvasive fibrosis staging) and longitudinal surveillance (colonoscopy in PSC‐IBD, abdominal imaging for hepatobiliary cancer surveillance and CA 19‐9 testing). Prescribing patterns for ursodeoxycholic acid (UDCA) were also characterised. Multivariable logistic regression was used to evaluate demographic, clinical and socioeconomic predictors of adherence. Results At diagnosis, 78.8% of eligible patients with available data underwent colonoscopy to establish IBD status, and 45% underwent noninvasive fibrosis staging. During follow‐up, only 30%–35% of patients with PSC‐IBD underwent colonoscopy annually, while abdominal imaging for hepatobiliary cancer surveillance declined from 74% at Year 1 to 51% by Year 4. CA 19‐9 testing was documented in 47% over 5‐year period. UDCA was prescribed in 51% at baseline, with median dose of 12.5 mg/kg/day. Socioeconomic factors, including lower education and household income, were associated with reduced adherence, while cirrhosis strongly predicted completion of surveillance imaging. Conclusions Adherence to guideline‐based care in PSC remains suboptimal in North America Suboptimal adherence was observed for strongly recommended practices with longstanding guideline support (colonoscopy to establish IBD status; annual CRC surveillance in PSC‐IBD) as well as practices where guideline consensus has evolved more recently or where societies differ (baseline fibrosis assessment; hepatobiliary cancer imaging). Efforts to standardise care and address socioeconomic barriers are urgently needed to improve outcomes.
Incidence of secondary intraocular lens implantation in school-aged children left aphakic to age 4.5 years in the Infant Aphakia Treatment Study
Drews-Botsch, Carolyn, VanderVeen, Deborah, Bothun, Erick, Wilson, Lorri B., Wilson, M E, Lambert, Scott R. , Group, for the Infant Aphakia Treatment Study, Drews‐Botsch, Carolyn , Wilson, M. Edward

Mayo Clinic

Journal of Cataract & Refractive Surgery | April 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/j.jcrs.0000000000001957 | PMID 41962549 Get It

Purpose: To determine the incidence of secondary IOL implantation in a cohort of children randomized to aphakia after unilateral congenital cataract surgery. Setting: Twelve clinical sites in the United States. Design: Randomized clinical trial. Data regarding secondary IOL implantation was collected retrospectively when patients were age 10½ years. Methods: We calculated the cumulative incidence of secondary IOL implantation in participants in the Infant Aphakia Treatment Study (IATS) who were randomized to aphakia to age 4½ years and were followed at age 10½ years. Results: Twenty-two (43%, 95% CI 29%,58%) of the 51 participants left aphakic to age 4½ years who had better than light perception vision at age 4½ years received a secondary IOL by age 10½. More than half (59%) of these were implanted by age 6 (Median 64.5 months, IQR 60,80). Secondary IOLs were implanted in children with good visual acuity (<20/40), as well as those with poor visual outcomes (>20/200) (39% and 44% respectively). Children who received a secondary IOL did not report less contact lens wear than those remaining aphakic (average of 94% of waking hours versus 90%, respectively). However, the proportion of children receiving a secondary IOL varied substantially by study center. Conclusions: Many children with unilateral congenital cataract who are initially left aphakic remain aphakic throughout the elementary school years. Practice patterns and family preference seem to be important drivers of the decision to implant a secondary IOL in these children.